Biofrontera (BFRI) Projected to Post Earnings on Friday

Biofrontera (NASDAQ:BFRI) is expected to release its Q4 2025 results after the market closes on Friday, April 3rd. Analysts expect the company to announce earnings of $0.1950 per share and revenue of $16.1460 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, March 19th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.29 by $0.21. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. The firm had revenue of $17.10 million during the quarter, compared to analyst estimates of $16.15 million. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Price Performance

Shares of NASDAQ:BFRI opened at $0.81 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $9.43 million, a PE ratio of -0.79 and a beta of 0.61. The firm’s 50 day moving average price is $0.87 and its 200-day moving average price is $0.88. Biofrontera has a twelve month low of $0.54 and a twelve month high of $1.19.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. increased its position in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th biggest position. Rosalind Advisors Inc. owned about 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.